Skip to main content

Table 1 Demographic and clinical data of amisulpride and placebo groups at baseline

From: Amisulpride augmentation therapy improves cognitive performance and psychopathology in clozapine-resistant treatment-refractory schizophrenia: a 12-week randomized, double-blind, placebo-controlled trial

Item

Amisulpride (n = 40)

Placebo (n = 40)

X2 or F(P)

Dropouts (n = 9)

Completers (n = 71)

X2 or F(P)

Age (years, mean ± SD)

46.60 ± 9.36

47.95 ± 7.20

0.52 (0.48)

45.33 ± 4.80

47.52 ± 8.67

0.54 (0.46)

Sex (n, male/female)

19/21

22/18

0.45 (0.50)

4/5

36/35

0.08 (0.78)

BMI (kg/m2, mean ± SD)

24.76 ± 3.47

23.06 ± 2.84

4.85 (0.03)

23.00 ± 0.99

24.02 ± 3.43

1.05 (0.31)

Education (years, mean ± SD)

11.48 ± 2.46

11.10 ± 2.26

0.27 (0.61)

10.78 ± 1.48

11.35 ± 2.44

0.75 (0.39)

Age of onset (years, mean ± SD)

22.70 ± 5.32

23.45 ± 6.26

0.26 (0.60)

23.89 ± 4.37

22.97 ± 5.95

0.38 (0.54)

Illness duration (years, mean ± SD)

23.05 ± 5.65

23.73 ± 6.45

0.19 (0.66)

24.38 ± 4.52

23.26 ± 6.22

0.39 (0.54)

Clozapine dose (mg/d, mean ± SD)

438.75 ± 32.99

447.50 ± 37.47

1.21 (0.28)

441.67 ± 30.62

443.31 ± 36.10

0.07 (0.80)

Serum clozapine level (ng/ml, mean ± SD)

478.05 ± 81.17

491.05 ± 80.17

0.56 (0.46)

484.11 ± 61.17

484.61 ± 82.90

0.01 (0.91)

PANSS total score (mean ± SD)

82.28 ± 8.54

79.53 ± 6.71

2.59 (0.11)

79.44 ± 4.33

81.08 ± 8.09

0.41 (0.53)

  P subscore

19.40 ± 6.54

20.73 ± 3.90

1.44 (0.23)

19.11 ± 4.11

20.18 ± 5.54

0.30 (0.59)

  N subscore

21.15 ± 7.45

18.98 ± 4.69

2.86 (0.10)

21.78 ± 4.21

19.85 ± 6.49

0.94 (0.34)

  G subscore

41.50 ± 6.33

39.83 ± 3.55

2.17 (0.15)

38.67 ± 3.71

40.92 ± 5.29

1.91 (0.17)

RBANS total score (mean ± SD)

59.38 ± 7.71

60.28 ± 10.14

0.23 (0.64)

59.44 ± 5.73

59.87 ± 9.32

0.02 (0.89)

  Immediate memory

59.43 ± 9.65

59.83 ± 10.68

0.05 (0.83)

60.33 ± 3.35

59.54 ± 11.25

0.04 (0.83)

  Visuospatial/construction

67.50 ± 12.23

68.65 ± 11.97

0.11 (0.74)

68.11 ± 5.18

68.07 ± 12.67

0.001 (0.98)

  Language

71.15 ± 14.02

71.63 ± 13.86

0.08 (0.78)

70.22 ± 5.87

71.54 ± 14.58

0.07 (0.79)

  Attention

73.65 ± 9.68

73.75 ± 11.52

0.26 (0.61)

72.89 ± 5.13

73.80 ± 11.41

0.04 (0.84)

  Delayed memory

57.93 ± 7.71

61.03 ± 10.14

1.52 (0.22)

59.00 ± 6.93

59.54 ± 10.11

0.02 (0.89)

SANS (mean ± SD)

45.18 ± 15.38

43.13 ± 14.36

0.36 (0.55)

42.56 ± 6.80

44.38 ± 11.53

0.12 (0.73)

CGI-S (mean ± SD)

5.03 ± 0.70

4.90 ± 0.71

0.49 (0.49)

5.11 ± 0.78

4.94 ± 0.70

0.42 (0.52)

CGI-I (mean ± SD)

4.06 ± 0.22

4.03 ± 0.16

0.17 (0.68)

4.11 ± 0.33

4.03 ± 0.17

1.30 (0.26)

CGI-E (mean ± SD)

13.60 ± 0.50

13.58 ± 0.50

0.34 (0.56)

13.44 ± 0.53

13.61 ± 0.49

0.59 (0.45)

  1. BMI body mass index, PANSS Positive and Negative Syndrome Scale, P positive symptom, N negative symptom, G general psychopathology, RBANS Repeatable Battery for the Assessment of Neuropsychological Status, CGI Clinical Global Impression scale, CGI-S CGI severity, CGI-I CGI improvement, CGI-E CGI efficacy